The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2021 | Learnings from the FOCUS4 trial
Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, provides an overview of the lessons learnt from the molecularly stratified FOCUS4 trial (EudraCT Number: 2012-005111-12), which assessed either capecitabine (FOCUS4-N), or adavocertib (FOCUS4-C) in patients with metastatic bowel cancer. Dr Seligmann highlights how many aspects of the trial have changed over time, including how the patients were stratified, as well as the importance of progression free survival (PFS) as a primary endpoint. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.
Disclosures
Dr Seligmann has received honoraria/travel/consultancy fees from Servier, Merck Serono, Pierre Fabre, Roche Diagnostics, BMS, and GI Connect.
